Sweeping U.S. policy changes under Health Secretary Robert F. Kennedy Jr. are having a chilling effect on vaccine makers as ...
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company ...
Health Canada is planning to speed up reviews of some drugs by piggybacking on the decisions of foreign regulators, including ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Novavax said on Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Non-exclusive license allows for development by Pfizer to utilize Matrix-M® for up to two disease areas with its ...
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for ...
TAIPEI (Taiwan News) — Taiwan reported a nearly 12% weekly increase in influenza, with health authorities warning that cases ...
Detailed price information for Halozyme Therapeutic (HALO-Q) from The Globe and Mail including charting and trades.
Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...
In a report released today, Pete Stavropoulos from Cantor Fitzgerald maintained a Buy rating on Axsome Therapeutics, with a price target of $153.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results